Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 286.00
Bid: 287.00
Ask: 290.00
Change: -2.00 (-0.69%)
Spread: 3.00 (1.045%)
Open: 290.00
High: 290.00
Low: 286.00
Prev. Close: 288.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK shareholder meetings calendar - next 7 days

Wed, 20th Apr 2022 16:05

Thursday 21 April 
Alliance Trust PLCAGM
Ibstock PLCAGM
Journeo PLCAGM
Relx PLCAGM
STV Group PLCAGM
Ruffer Investment Co LtdEGM re share issue
Friday 22 April 
Bellevue Healthcare Trust PLCAGM
Faron Pharmaceuticals LtdAGM
Murray International Trust PLCAGM
Monday 25 April 
Belluscura PLCAGM
Capital Gearing Trust PLCGM re non pre-emptive share issue
Cloudbreak Discovery PLCGM re Crescita equity drawdown agreement
Hikma Pharmaceuticals PLCAGM
JPMorgan US Smaller Cos Investment Trust PLCAGM
Polymetal International PLCAGM
Symphony International Holdings LtdAGM
Tuesday 26 April 
Aquis Exchange PLCAGM
Elementis PLCAGM
GlobalData PLCAGM
Oriole Resources PLCAGM
RPS Group PLCAGM
SigmaRoc PLCAGM
Taylor Wimpey PLCAGM
Tissue Regenix Group PLCAGM
Wednesday 27 April 
Drax Group PLCAGM
EP Global Opportunities Trust PLCAGM
Global Invacom Group LtdAGM
Hutchmed (China) LtdAGM
London Stock Exchange Group PLCAGM
McKay Securities PLCGM re Workspace offer
Nichols PLCAGM
Persimmon PLCAGM
Primary Health Properties PLCAGM
VH Global Sustainable Energy Opportunities PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2020 15:54

UK TRADING UPDATE SUMMARY: Feedback And Tissue Regenix Secure CE Marks

UK TRADING UPDATE SUMMARY: Feedback And Tissue Regenix Secure CE Marks

Read more
29 May 2020 17:06

UK TRADING UPDATE SUMMARY: New Trend Lifestyle Sees Extended Turmoil

UK TRADING UPDATE SUMMARY: New Trend Lifestyle Sees Extended Turmoil

Read more
17 Apr 2020 13:19

Hutchison China Gets US FDA Fast Track Status For Surufatinib

Hutchison China Gets US FDA Fast Track Status For Surufatinib

Read more
3 Mar 2020 14:24

Hutchison China Sees Loss Widen But Lays "Foundations" In 2019

Hutchison China Sees Loss Widen But Lays "Foundations" In 2019

Read more
25 Feb 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
12 Feb 2020 17:27

FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials

By Tamara Mathias, Roxanne Liu and Manojna MaddipatlaFeb 12 (Reuters) - The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of ...

Read more
10 Feb 2020 07:36

Hutchison Chi-Med shares up on updated results from 'CALYPSO'

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi' (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma (PRCC) on Monday.

Read more
23 Jan 2020 15:06

Hutchison China Prices USD110 Million American Depositary Share Offer

Hutchison China Prices USD110 Million American Depositary Share Offer

Read more
22 Jan 2020 10:44

Hutchison China Plans USD110 Million American Depositary Share Offer

Hutchison China Plans USD110 Million American Depositary Share Offer

Read more
20 Jan 2020 16:00

Hutchison Chi-Med upbeat on progress with surufatinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine tumours - pancreatic (SANET-p) has completed a pre-planned interim analysis.

Read more
20 Jan 2020 11:37

Hutchinson China Reports Early Success Of Surufatinib Phase III Study

Hutchinson China Reports Early Success Of Surufatinib Phase III Study

Read more
13 Jan 2020 09:01

Hutchison China Starts Phase II Study For Cancer Treatment In China

Hutchison China Starts Phase II Study For Cancer Treatment In China

Read more
20 Dec 2019 15:48

Hutchison Chi-Med gets priority review for 'surufatinib' in China

(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority Review' status to its new drug application for 'surufatinib', for the treatment of patients with advanced non-pancreatic neuroendocrine tumours.

Read more
20 Dec 2019 12:10

Hutchison China Hails "Positive Step" For Cancer Treatment In China

Hutchison China Hails "Positive Step" For Cancer Treatment In China

Read more
28 Nov 2019 14:58

Hutchison China MediTech's Cancer Treatment Joins Key China State List

Hutchison China MediTech's Cancer Treatment Joins Key China State List

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.